Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08VRO
|
|||
| Former ID |
DAP001394
|
|||
| Drug Name |
Ketanserin
|
|||
| Synonyms |
Ketanserina; Ketanserine; Ketanserinum; Ketaserin; Perketal; Serefrex; Sufrexal; Taseron; Ketanserina [INN-Spanish]; Ketanserine [INN-French]; Ketanserinum [INN-Latin]; R 41,468; R-41468; [3H]-Ketanserin; Ketanserin (USAN/INN); Ketanserin [USAN:BAN:INN]; R-41,468; (+)-3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2,4-(1H,3H)-quinazolinedione; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione; 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione; 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Janssen Pharmaceutica
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22FN3O3
|
|||
| Canonical SMILES |
C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O
|
|||
| InChI |
1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
|
|||
| InChIKey |
FPCCSQOGAWCVBH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 74050-98-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9667, 5316930, 7849422, 7979679, 8152420, 11113781, 11485462, 11489529, 12013738, 14756745, 26612919, 26680573, 26747132, 26747133, 26751962, 29222941, 47440431, 47440432, 47810935, 47959944, 48416147, 49658635, 49689467, 49689468, 49698468, 50041095, 50103875, 50104634, 50284786, 53789966, 57322008, 81041139, 85209483, 85787802, 85788847, 90340810, 91011753, 92124961, 92308193, 92309154, 92719783, 103167043, 103857213, 104171396, 104304625, 118842179, 124360771, 124637348, 124757882, 124886722
|
|||
| ChEBI ID |
CHEBI:6123
|
|||
| SuperDrug ATC ID |
C02KD01
|
|||
| SuperDrug CAS ID |
cas=074050989
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2 receptor (5HT2R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 88). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.